Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Non-Hodgkin 6Lymphoma, Large-Cell, Immunoblastic 6Hodgkin Disease 6Burkitt Lymphoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Sezary Syndrome 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Prostatic Neoplasms 4Multiple Myeloma 4Melanoma 4Lung Neoplasms 4Leukemia 4Immunoblastic Lymphadenopathy 4Carcinoma, Non-Small-Cell Lung 4Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Blast Crisis 3

Interventions

Magnetic Resonance Spectroscopy 17Iodine-131 16lenvatinib 13trametinib 12Thyrotropin Alfa 11Sorafenib 11pembrolizumab 10dabrafenib 10Paclitaxel 9vandetanib 8Thyroxine 8Surgical Procedures, Operative 7Sunitinib 7selpercatinib 6cabozantinib 6Nivolumab 6Fluorodeoxyglucose F18 6Everolimus 6pazopanib 5Vemurafenib 5Thyroidectomy 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Cyclophosphamide 5Cisplatin 5Biopsy 5apatinib 4anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thyroid Neoplasms × tanespimycin × Clear all
NCT00118248 2017-02-15

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 10 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡